{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:57:30Z","timestamp":1789804650728,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Harvard Medical School Center for Global Health Delivery - Dubai"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2MD015102"],"award-info":[{"award-number":["DP2MD015102"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To ensure patient-centered tuberculosis preventive treatment, it is important to consider factors that make it easier for patients to complete treatment. However, there is little published literature about patient preferences for different preventive treatment regimen options, particularly from countries with high tuberculosis burdens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a qualitative research study using a framework analysis approach to understand tuberculosis preventive treatment preferences among household contacts. We conducted three focus group discussions with 16 members of families affected by tuberculosis in Lima, Peru. Participants were asked to vote for preferred preventive treatment regimens and discuss the reasons behind their choices. Coding followed a deductive approach based on prior research, with data-driven codes added.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 7 (44%) participants voted for 3\u2009months isoniazid and rifapentine, 4 (25%) chose 3\u2009months isoniazid and rifampicin, 3 (19%) chose 4\u2009months rifampicin, and 2 (13%) chose 6\u2009months isoniazid. Preferences for shorter regimens over 6\u2009months of isoniazid were driven by concerns over \u201cgetting tired\u201d or \u201cgetting bored\u201d of taking medications, the difficulty of remembering to take medications, side effects, and interference with daily life. For some, weekly dosing was perceived as being easier to remember and less disruptive, leading to a preference for 3\u2009months isoniazid and rifapentine, which is dosed weekly. However, among caregivers, having a child-friendly formulation was more important than regimen duration. Caregivers reported difficulty in administering pills to children, and preferred treatments available as syrup or dispersible formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is demand for shorter regimens and child-friendly formulations for tuberculosis preventive treatment in high-burden settings. Individual preferences differ, suggesting that patient-centered care would best be supported by having multiple shorter regimens available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-020-10098-5","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T08:28:51Z","timestamp":1610353731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-2599","authenticated-orcid":false,"given":"Courtney M.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana K.","family":"Millones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome T.","family":"Galea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Puma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes C.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan","family":"Keshavjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"10010","key":"10098_CR1","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","volume":"386","author":"MX Rangaka","year":"2015","unstructured":"Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet. 2015;386(10010):2344\u201353.","journal-title":"Lancet."},{"key":"10098_CR2","unstructured":"Global Tuberculosis Report 2019. Geneva: World Health Organization; 2019."},{"issue":"8","key":"10098_CR3","doi-asserted-by":"publisher","first-page":"e0182185","DOI":"10.1371\/journal.pone.0182185","volume":"12","author":"D Szkwarko","year":"2017","unstructured":"Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: a mixed-methods systematic review. PLoS One. 2017;12(8):e0182185.","journal-title":"PLoS One"},{"issue":"11","key":"10098_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"key":"10098_CR5","doi-asserted-by":"crossref","unstructured":"Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. Pediatrics. 2018;141(2):e20172838.","DOI":"10.1542\/peds.2017-2838"},{"issue":"11","key":"10098_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","volume":"22","author":"MM Macaraig","year":"2018","unstructured":"Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018;22(11):1344\u20139.","journal-title":"Int J Tuberc Lung Dis."},{"key":"10098_CR7","doi-asserted-by":"crossref","unstructured":"Ronald LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, Benedetti A, Boivin JF, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. Eur Respir J. 2020;55(3):1902048.","DOI":"10.1183\/13993003.02048-2019"},{"issue":"2","key":"10098_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5588\/ijtld.17.0608","volume":"22","author":"A Odone","year":"2018","unstructured":"Odone A, Roberts B, Dara M, van den Boom M, Kluge H, McKee M. People- and patient-centred care for tuberculosis: models of care for tuberculosis. Int J Tuberc Lung Dis. 2018;22(2):133\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10098_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.5588\/ijtld.17.0809","volume":"22","author":"Y Hirsch-Moverman","year":"2018","unstructured":"Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, Hesseling AC, Howard AA, et al. Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study. Int J Tuberc Lung Dis. 2018;22(8):858\u201362.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"6","key":"10098_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jval.2011.05.003","volume":"14","author":"N Guo","year":"2011","unstructured":"Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment. Value Health. 2011;14(6):937\u201343.","journal-title":"Value Health"},{"issue":"4","key":"10098_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5588\/ijtld.18.0740","volume":"24","author":"HY Kim","year":"2020","unstructured":"Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis. 2020;24(4):396\u2013402.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"6","key":"10098_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-001950","volume":"4","author":"D Szkwarko","year":"2019","unstructured":"Szkwarko D, Hirsch-Moverman Y. One size does not fit all: preventing tuberculosis among child contacts. BMJ Glob Health. 2019;4(6):e001950.","journal-title":"BMJ Glob Health"},{"key":"10098_CR13","volume-title":"WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization; 2020."},{"issue":"2","key":"10098_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.7748\/nr2011.01.18.2.52.c8284","volume":"18","author":"J Smith","year":"2011","unstructured":"Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse Res. 2011;18(2):52\u201362.","journal-title":"Nurse Res"},{"key":"10098_CR15","first-page":"1","volume":"10","author":"R Penaloza","year":"2019","unstructured":"Penaloza R, Navarro JI, Jolly PE, Junkins A, Seas C, Otero L. Health literacy and knowledge related to tuberculosis among outpatients at a referral hospital in Lima. Peru Res Rep Trop Med. 2019;10:1\u201310.","journal-title":"Peru Res Rep Trop Med"},{"key":"10098_CR16","doi-asserted-by":"crossref","unstructured":"Shu E, Sobieszczyk ME, Sal Y Rosas VG, Segura P, Galea JT, Lecca L, et al. Knowledge of tuberculosis and vaccine trial preparedness in Lima, Peru. Int J Tuberc Lung Dis. 2017;21(12):1288\u201393.","DOI":"10.5588\/ijtld.17.0116"},{"issue":"5","key":"10098_CR17","doi-asserted-by":"publisher","first-page":"e0217104","DOI":"10.1371\/journal.pone.0217104","volume":"14","author":"CM Yuen","year":"2019","unstructured":"Yuen CM, Millones AK, Contreras CC, Lecca L, Becerra MC, Keshavjee S. Tuberculosis household accompaniment to improve the contact management cascade: a prospective cohort study. PLoS One. 2019;14(5):e0217104.","journal-title":"PLoS One"},{"issue":"3","key":"10098_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/tmi.13350","volume":"25","author":"L Otero","year":"2020","unstructured":"Otero L, Battaglioli T, Rios J, De la Torre Z, Trocones N, Ordonez C, et al. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data. Tropical Med Int Health. 2020;25(3):346\u201356.","journal-title":"Tropical Med Int Health"},{"issue":"2","key":"10098_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5588\/ijtld.16.0624","volume":"21","author":"SS Chiang","year":"2017","unstructured":"Chiang SS, Roche S, Contreras C, Del Castillo H, Canales P, Jimenez J, et al. Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study. Int J Tuberc Lung Dis. 2017;21(2):154\u201360.","journal-title":"Int J Tuberc Lung Dis."},{"key":"10098_CR20","unstructured":"Estrategia Sanitaria Nacional de Prevenci\u00f3n y Control de la Tuberculosis. Norma t\u00e9cnica de salud para la atenci\u00f3n integral de las personas afectadas por tuberculosis. Lima: Ministerio de Salud; 2013."},{"key":"10098_CR21","volume-title":"web application for managing, analyzing, and presenting qualitative and mixed method research data","author":"Dedoose Version 8.0.35","year":"2018","unstructured":"Dedoose Version 8.0.35. web application for managing, analyzing, and presenting qualitative and mixed method research data. Los Angeles, CA: SocioCultural Research Consultants, LLC; 2018."},{"issue":"1","key":"10098_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijpharm.2016.07.054","volume":"514","author":"SR Ranmal","year":"2016","unstructured":"Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: insights into end-user perceptions, preferences and practices from the Children's acceptability of Oral formulations (CALF) study. Int J Pharm. 2016;514(1):296\u2013307.","journal-title":"Int J Pharm"},{"issue":"10 Suppl2","key":"10098_CR23","first-page":"S274","volume":"24","author":"Y Hirsch-Moverman","year":"2020","unstructured":"Hirsch-Moverman Y, Strauss M, George G, Mafukidze A, Dube GS, Mutiti A, et al. Tuberculosis preventive treatment preferences among children in Eswatini: a mixed methods study. Int J Tuberc Lung Dis. 2020;24(10 Suppl2):S274.","journal-title":"Int J Tuberc Lung Dis."},{"key":"10098_CR24","doi-asserted-by":"publisher","unstructured":"Chiang SS, Brooks MB, Jenkins HE, Rubenstein D, Seddon JA, van de Water BJ, et al. Concordance of drug resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa613.","DOI":"10.1093\/cid\/ciaa613"},{"issue":"7","key":"10098_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/1471-0528.15027","volume":"125","author":"KB Simmons","year":"2018","unstructured":"Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018;125(7):804\u201311.","journal-title":"BJOG."},{"issue":"12","key":"10098_CR26","first-page":"1499","volume":"8","author":"A Fernandez-Villar","year":"2004","unstructured":"Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499\u2013505.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"5","key":"10098_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1164\/rccm.201806-1053PP","volume":"199","author":"S Keshavjee","year":"2019","unstructured":"Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, et al. Moving toward tuberculosis elimination. Critical issues for research in diagnostics and therapeutics for tuberculosis infection. Am J Respir Crit Care Med. 2019;199(5):564\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10098_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5588\/ijtld.17.0486","volume":"22","author":"S Swindells","year":"2018","unstructured":"Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, et al. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018;22(2):125\u201332.","journal-title":"Int J Tuberc Lung Dis."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-10098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-020-10098-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-10098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T08:34:04Z","timestamp":1610354044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-10098-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10098"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-10098-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.17.20133942","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants gave verbal informed consent for participation in the focus group. A waiver of written informed consent was granted on the basis that the study posed minimal risk to participants and that since a written informed consent form would be the only study document recording participants\u2019 names, anonymity could best be assured by using verbal informed consent. Transport and compensation for time equivalent to 10 USD was provided. This study was approved by the institutional review boards of Harvard Medical School and the Universidad Peruana Cayetano Heredia.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}